Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.
Also called NCT06148649
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 234 participants
- Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Registry
-
NCT06148649
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06148649. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-10 (actual); primary completion 2025-02-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HEC88473, Placebo, Dulaglutide
- Lead sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Record details
- Record id
cardio:ct-nct06148649- Content hash
ca7f1dd0e302dfd49ffcf2e44fe7978e3796ee970f84c18bb7d1842873e5758c